Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JCOG1212 RADPLAT-MSC for locally advanced maxillary sinus cancer
jRCTs031180004Active, not recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- May 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of cisplatin in maxillary sinus squamous cell carcinoma (MS-SCC), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoints: 3-year overall survival and Incidence of dose-limiting toxicity. Started May 2014; status: active, not recruiting.
02
Drugs
cisplatin
03
Conditions
maxillary sinus squamous cell carcinoma (MS-SCC)
Beyond the preview
Go deeper on jRCTs031180004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031180004.